-
公开(公告)号：US09631004B2
公开(公告)日：2017-04-25
申请号：US15215329
申请日：2016-07-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
CPC classification number: A61K38/1825 , A61K38/00 , A61K45/06 , A61K47/60 , A61K47/64 , C07K14/50 , C07K2319/00 , C07K2319/30
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US20220185856A1
公开(公告)日：2022-06-16
申请号：US17555633
申请日：2021-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US10377806B2
公开(公告)日：2019-08-13
申请号：US15979881
申请日：2018-05-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US10189883B2
公开(公告)日：2019-01-29
申请号：US15460917
申请日：2017-03-16
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
5.发明授权公开(公告)号：US12247058B2
公开(公告)日：2025-03-11
申请号：US17555633
申请日：2021-12-20
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Nucleic acids encoding modified FGF-21 polypeptides, optionally containing at least one non-codon encoding a naturally-encoded amino acid, and vectors and cells containing are provided. These nucleic acids can be used to express the modified FGF-21 polypeptide encoded thereby. The expressed FGF-21 polypeptides may be used as therapeutics, e.g., in the treatment of diseases associated with fibrosis.
-
Patent Agency Ranking
公开(公告)号：US11248031B2
公开(公告)日：2022-02-15
申请号：US16455990
申请日：2019-06-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US10221438B2
公开(公告)日：2019-03-05
申请号：US15363724
申请日：2016-11-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
IPC: A61K38/00 , A61K47/62 , A61K47/64 , C07K14/50 , C07K14/78 , C12N15/62 , C12P21/00 , C07K14/435 , C07K14/575
Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
-
公开(公告)号：US10934572B2
公开(公告)日：2021-03-02
申请号：US16244921
申请日：2019-01-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Michael L. Gosselin , David Fabrizio , Joanna F. Swain , Tracy Mitchell , Ray Camphausen , Sharon T. Cload , Eric Furfine , Paul E. Morin , Ranjan Mukherjee , Simeon I. Taylor
IPC: C12P21/00 , C12N15/62 , A61K47/62 , A61K47/64 , C07K14/78 , C07K14/435 , C07K14/50 , C07K14/575 , A61K38/00
Abstract: The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (10Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
-
公开(公告)号：US20190382460A1
公开(公告)日：2019-12-19
申请号：US16455990
申请日：2019-06-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
公开(公告)号：US20180243375A1
公开(公告)日：2018-08-30
申请号：US15979881
申请日：2018-05-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Paul E. Morin , Daniel Cohen , Ranjan Mukherjee , Timothy P. Reilly , Rose C. Christian , Dasa Lipovsek , Ray Camphausen , John Krupinski
IPC: A61K38/18
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K45/06 , A61K47/60 , A61K47/64 , C07K2319/00 , C07K2319/30
Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.033 seconds)
